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SPECTRAL TEHPORAL HAPPING OF SIGNAL-AVERAGED ECG IS A 
POWERFUL INDEPENDENT PREDICTOR OF INDUCIBLE VENTRICULAR 
TACWCARDIA. A HJLTIVARIATE ANALYSIS IN 132 PATIENTS. 
Macha Ip JR, c 3, Winters S, Verdino R, Tepper D, Comes 
JA. Mount Sinai ?iedical Center, Nev York, NY. 
AJCD 6726. 29fl4' 3.2&l 
“p=NS compared to AARx 
Seventeen of 61 p&(21%) died during a mean folbw-up of 16k7 mos. 
Seven had an AICD. Mortality from any cause a1 12.16, 24 mos for 
Veered with AARx and AICD were 13.5, 15.9, 25.4 and 13.1, 2 
38.6% respecthrely, p=NS. Freedom from cardiac mortality is shown : 
We analysed the predictive value of 5 variables in 
predicting ventricular tachycardia (VT) induction in 
132 patients vith coronary artery disease (n48) or 
cardiomyopathy (nm44). The variables vere: 1. The 
presenting symptoms- ventricular arrthymia (VA) 
(sustained or nonsustained VT) or syncopy. 2. Presence 
of aneurysm (AN), 3. Ejection fractiorr (EF<30% or 
EF>30%). 4. Time domain CTS) analysis of the signal 
averaged (Sk) ECG: abnomal if any one or more ?f the 




if the normality factor (NF) vas (30 in any one or more 
of the X,Y,Z leads. Univariate analysis identified VA, 
EF, AN, TD, STH as predictors of VT induction. 
1.0 
In summary, there appears to be no s fference In overall 
sunival or cardiac mortality between 
therapy can be defined vs those receive an AICD. Therefore 
drug testing remains a viable op kr the treatment of pts presen 
with ventricular tachyarrhythmias. 
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Andrew C. Rankin, Peter N. Smith, Lenore Hamilton, Hasan 
m j-r- Ruskin, Brian A. McGovern, 
ssachusetts General Hospital, Boston, M 
prospectively evaluated sotalol, a beta-adrenergic 
receptor blocking agent with class III 
action, in 162 Pts with drug refr 
antiarrhythmic 
arrhythmias. mere were 130 men, 
66(mean 61) years. The majority(6 
disease and the mean LV ejection 
Clinical arrhythmia was ventricular tachycardia(VT) in 
115, ventricular fibrillation (VP) in 29 and 
nonsustained VT (NSVT) in 16. sOtal was not ueed in 
Pts with uncoqxnsated congestive heart failure, Lv 
ejection fraction < 20% or severe bronchospasm. In 39 of 
131 Pts with sustdned ventricular arrhythmia induced by 
Prow 
arrhythmia. 
stimulation, sotalol suppressed the induced 
In another 36, sotalol was selected as the 
best therapeutic and tolerated antiarrhythmic drug even 
though VT/W remained inducible. 
discharged on long term oral 
Seventy-seven Pts were 
sot were tollowed 
for a maximux~ of 5 years, with a llo+up duration 
of 16.3(SD14.2) months. There were 5 sudden deaths, 6 
recurrences of non-fatal sustained arrhythmia and 5 Pts 
syqtcmatic NSVT durin 
ause of adverse effects 
lysis showed that the a 
90% at 6 months, 79% at 1 
hnnt-free Survival at 2 years for kts With no inducible 
VT or VP on sotalol ~116 64%. and for those still ~. ----- ----- 
inducible on sotalol was 544 (Pt0.05). seventeen of the 
29 (59%) Pts with VF at presentation were treated with 
long term sotalol, with M, recurrence of arrhVt.hmia 
during a mean follow-up of 19.1 (SD 15.3) am&L.-- 
Oooelusim: Sotalol is a well tolerated antiarrhythmic 
drug and, when inducible VT or VP is suppressed, 
provides effective long-term therapy, especially for Pts 
presenting with VF. 
VA 
p value <O.OOl 
EF<30 TD STH 
0.001 0.04 0.001 <0.0001 
Hultivariate analysis using stepwise logistic 
regression identified VA and STIl as the only 
independent predictors of VT inducibility. The 
probability of having inducible VT in a patient with VA 
and abnormal STIl is 09%. We conclude that STll is a 
poverful independent predictor of VT inducibility in 
patients vith coronary artery disease and 
cardiomyopathy. 
IS ELECTROCARDIOGRAM CBAOS AW INDEPENDENT PREDICTOR 
OF ELBCTROPBYSIOLOGIC IWDUCIBILITY? 
m&c w. f&&J., James M. Kammerling, Jodi A. Corum, 
Cherne Medical, Minneapolis, MN and Humana Heart 
Institute, Louisville, KY 
Intooduction: Although chaotic activity in the 
pulse rate implies a favorable prognosis, chaotic 
activity in the ECG voltage has been reported during 
fibrillation. We hypothesized that patients 
inducible for ventricular tachycardia (VTach) in 
electrophysiologic st.udies might have more ECG 
voltage chaos than noninducible patients and 
controls. 
thod: We evaluated a new ECG system that detects 
w levels of chaotic activity in the wide bandwidth 
(0.5 to 1500 Hz) ECG and reports it as a chaotic 
activity score (CAS). Patients (15) received the 
chaos ECG in advance of their EP studies. Age and 
gender matched controls (9) also received the chaos 
ECG. The device was unable to calculate a CAS in 5 
of the EP patients, possibly due to frequent ectopy; 
these 5 were then excluded. Of the 10 EP patients 
with chaos acores, 7 had inducible VTach and 3 did 
not. Controls were grouped with the non-inducible 
tients. 
rulta: Inducible patients had a higher CAS (104.8 
A9.6 VI 71.1 % 27.Q* pa.01). 1x3 %a ~~~g~veriage 
alysis, the CAS added independent information to 
histories of myocardial infarction and sustained 
VTach (p<.Ol) and increased the correlation (rz) 
from 0.74 to 0.90. The 3-variable model had a jack- 
knifed sensitivity of H6% (6/7) and a specificity of 
92% (11/12). 
Cornclusion: The chaos level in the ECG voltage was 
an independent predictor of VTach inducibility in 
this preliminary study and deserves further 
examination in larger studies. 
